RI 624

Identification

Generic Name
RI 624
DrugBank Accession Number
DB05892
Background

RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain. RI 624 is being developed by Rinat and is currently in Phase I clinical trials.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
Not Available

Pharmacology

Indication

Investigated for use/treatment in pain (acute or chronic).

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

RI 624 works very differently from all currently approved drugs for the treatment of pain. Unlike the other pain relievers, RI 624 primarily works to inhibit the production of NGF, rather than COX-2 for instance. NGF is a member of a family of proteins known as neurotrophins that plays a role in the growth of certain sensory neurons, an activity that appears to end at birth or shortly afterward. Pain-causing injury or inflammation induces the synthesis and stimulates the release of NGF in later stages of life. Scientific observation has shown that the up-regulation of NGF is a common component of the inflammatory response that initiates and sustains the pain sensation. NGF therefore appears to have profound direct and indirect stimulatory effects on the primary sensory neurons that mediate pain. RI 624 essentially blocks NGF from binding to its target area and thus impedes an imflammatory response.

TargetActionsOrganism
UBeta-nerve growth factorNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with RI 624.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with RI 624.
AducanumabThe risk or severity of adverse effects can be increased when RI 624 is combined with Aducanumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with RI 624.
AlirocumabThe risk or severity of adverse effects can be increased when RI 624 is combined with Alirocumab.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910298

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Receptor signaling protein activity
Specific Function
Nerve growth factor is important for the development and maintenance of the sympathetic and sensory nervous systems. Extracellular ligand for the NTRK1 and NGFR receptors, activates cellular signal...
Gene Name
NGF
Uniprot ID
P01138
Uniprot Name
Beta-nerve growth factor
Molecular Weight
26958.53 Da

Drug created at November 18, 2007 18:28 / Updated at June 12, 2020 16:52